Positive data readout from interim analysis in the phase Ⅲ trial in females in Indonesia of the Nonavalent HPV.
Positive data readout from interim analysis in the phase Ⅲ trial in females in China of the Nonavalent HPV.
Trivalent HPV Vaccine Gains Priority Review Status

An application submitted for listing on the HKEX
Drug manufacturing license obtained for the Kunming manufacturing facility
Positive data readout from interim analysis in the phase Ⅲ trial of the Trivalent HPV

Successful debut on the Beijing Stock Exchange as the first vaccine company
IND approval obtained and phase Ⅲ trial commenced for the Nonavalent HPV in Indonesia

Phase Ⅲ trial commenced for the Nonavalent HPV in males

Construction of the Kunming manufacturing facility initiated
Pre-IPO round of RMB 1.015 billion completed

Phase Ⅲ study of the Trivalent HPV commenced in females
Phase Ⅲ study of the Nonavalent HPV commenced in females
IND approval obtained for the Nonavalent HPV in males
Series C round of RMB 651 million completed

Collaboration agreement reached with Chengda Biotechnology on the development and commercialization of the 15-valent HPV
Series B round of RMB 50.71 million completed

IND approval obtained for the Nonavalent HPV (female indication)

IND approval obtained for the Trivalent HPV

BHGB Listed on the NEEQ (stock code: 833575)

BHGB certified as a High and New Technology Enterprise (HNTE)

BHGB founded as a limited liability company
Investment secured from SCGC and Sirius Group